Advertisement

Enhancement of the Penetration of Topically Applied Substances by Tissue-Tolerable Plasma

  • J. Lademann
  • H. Richter
  • A. Kramer
  • O. Lademann
Chapter

Abstract

Drug delivery through the skin barrier is a topic of high interest in cosmetology and dermatology. The disruption of the skin barrier is a common method to stimulate skin penetration. In the present chapter tissue tolerable plasma is used to damage the skin barrier, enabling topically applied substances to effectively pass the stratum corneum. Subsequently to plasma-tissue interaction the skin barrier recovers immediately. Topically applied drugs have to be applied before the plasma treatment onto the skin. In this case, the plasma chemical reaction of the drug has to be prevented by using plasma resistant nanocontainers.

Keywords

Tissue-tolerable plasma Skin barrier Drug delivery Nanoparticles Laser scanning microscopy Dye 

References

  1. 1.
    Lichterfeld A, Hauss A, Surber C, Peters T, Blume-Peytavi U, Kottner J. Evidence-based skin care: a systematic literature review and the development of a basic skin care algorithm. J Wound Ostomy Continence Nurs. 2015;42(5):501–24.CrossRefGoogle Scholar
  2. 2.
    Fowler JE, Woolery-Lloyd H, Waldorf H, Saini R. Innovations in natural ingredients and their use in skin care. J Drugs Dermatol. 2010;9(6):S72–81.PubMedGoogle Scholar
  3. 3.
    Rosenkrantz W. Practical applications of topical therapy for allergic, infectious, and seborrheic disorders. Clin Tech Small Anim Pract. 2006;21(3):106–16.CrossRefGoogle Scholar
  4. 4.
    Richters RJ, Falcone D, Uzunbajakava NE, Varghese B, Caspers PJ, Puppels GJ, van Erp PE, van de Kerkhof PC. Sensitive skin: assessment of the skin barrier using confocal raman microspectroscopy. Skin Pharmacol Physiol. 2017;30(1):1–12.CrossRefGoogle Scholar
  5. 5.
    Nielsen JB, Benfeldt E, Holmgaard R. Penetration through the skin barrier. Curr Probl Dermatol. 2016;49:9.Google Scholar
  6. 6.
    Maibach HI, Feldman RJ. Occlusive dressing for the nose and ears. Arch Dermatol. 1966;93(4):465.CrossRefGoogle Scholar
  7. 7.
    Choi WI, Lee JH, Kim JY, Kim JC, Kim YH, Tae G. Efficient skin permeation of soluble proteins via flexible and functional nano-carrier. J Control Release. 2012;157(2):272–8.CrossRefGoogle Scholar
  8. 8.
    Zhang H, Zhai Y, Yang X, Zhai G. Breaking the skin barrier: achievements and future directions. Curr Pharm Des. 2015;21(20):2713–24.CrossRefGoogle Scholar
  9. 9.
    Goldberg EP, Hadba AR, Almond BA, Marotta JS. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol. 2002;54(2):159–80.CrossRefGoogle Scholar
  10. 10.
    Jacobi U, Kaiser M, Toll R, Mangelsdorf S, Audring H, Otberg N, et al. Porcine ear skin: an in vitro model for human skin. Skin Res Technol. 2007;13(1):19–24.CrossRefGoogle Scholar
  11. 11.
    Ulrich C, Kluschke F, Patzelt A, Vandersee S, Czaika VA, Richter H, et al. Clinical use of cold atmospheric pressure argon plasma in chronic leg ulcers: a pilot study. J Wound Care. 2015;24(5):196. 8–200, 2–3.CrossRefGoogle Scholar
  12. 12.
    Lademann O, Kramer A, Richter H, Patzelt A, Meinke MC, Czaika V, et al. Skin disinfection by plasma-tissue interaction: comparison of the effectivity of tissue-tolerable plasma and a standard antiseptic. Skin Pharmacol Physiol. 2011;24(5):284–8.CrossRefGoogle Scholar
  13. 13.
    Lademann J, Richter H, Alborova A, Humme D, Patzelt A, Kramer A, et al. Risk assessment of the application of a plasma jet in dermatology. J Biomed Opt. 2009;14(5):054025.CrossRefGoogle Scholar
  14. 14.
    Lademann O, Richter H, Meinke MC, Patzelt A, Kramer A, Hinz P, et al. Drug delivery through the skin barrier enhanced by treatment with tissue-tolerable plasma. Exp Dermatol. 2011;20(6):488–90.CrossRefGoogle Scholar
  15. 15.
    Wijenayake AU, Abayasekara CL, Pitawala HM, Bandara BM. Antimicrobial potential of two traditional herbometallic drugs against certain pathogenic microbial species. BMC Complement Altern Med. 2016;16:365.CrossRefGoogle Scholar
  16. 16.
    Jain C, Das S, Ramachandran VG, Saha R, Bhattacharya SN, Dar S. Malassezia yeast and cytokine gene polymorphism in atopic dermatitis. J Clin Diagn Res. 2017;11(3):DC01–DC5.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Lademann J, Patzelt A, Richter H, Lademann O, Baier G, Breucker L, et al. Nanocapsules for drug delivery through the skin barrier by tissue-tolerable plasma. Laser Phys Lett. 2013;10(8).CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • J. Lademann
    • 1
    • 2
  • H. Richter
    • 1
    • 2
  • A. Kramer
    • 3
  • O. Lademann
    • 4
  1. 1.Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu BerlinBerlinGermany
  2. 2.Department of DermatologyCenter of Experimental and Applied Cutaneous Physiology (CCP), Berlin Institute of HealthBerlinGermany
  3. 3.Institute of Hygiene and Environmental MedicineUniversity Medicine GreifswaldGreifswaldGermany
  4. 4.Clinic of Anesthesiology and Intensive TherapyUniversity Medicine RostockRostockGermany

Personalised recommendations